	Shopping Cart
Your cart contains 0 items : £0.00 ex shipping


Create an Account		Customer login

Ventolin Evohaler 100mcg

Price: only £1.75 (No VAT)
* Price shown per tablet / capsule.


	Key Points
		FREE SHIPPING ON THIS ITEM
		UK product supplied

Pack price equivalent (1 pack) is £1.75 (No VAT)

You must order the quantity stated on your prescription.

This product was added to our catalog on Monday 28 November, 2011.

[+] Prescription Only Medicine - Click here for important information.

This product is a prescription-only medication (POM). You cannot order this item unless you have a valid prescription from a UK registered medical practitioner.

The original prescription must be posted to us before we can dispense this drug.

You may download our FREEPOST address label (PDF format) and print your envelope, which will be treated as first class post.

Alternatively, address your envelope:

Freepost RSEH-KURS-LLHY
Hordle Pharmacy
26 Ashley Lane
Hordle, Lymington
SO41 0GA

Note: If you hand write the address, the envelope will be treated as 2nd class post. For your convenience, we will send you a supply of pre-printed envelopes with your order.

Please order the exact quantity stated on your prescription.

There is no VAT on prescription-only medications for human use.

Don't have a prescription?

If you do not have a valid UK prescription, you may get one from PharmaDoctor. PharmaDoctor work with us to provide an online consultation service that may lead to the issue of a prescription. If successful, you pay a fee to PharmaDoctor that includes prescription issue and the cost of the medicines.

To use the PharmaDoctor service, simply click the red button above to be referred through to PharmaDoctor.

Product Details

Ventolin Evohaler is a pressurised metered-dose inhaler delivering 100 micrograms of salbutamol (as Salbutamol Sulphate BP) per actuation. Ventolin Evohaler contains a new propellant (HFA 134a) and does not contain any chlorofluorocarbons.

Ventolin Evohaler provides short-acting (4 to 6 hour) bronchodilatation with fast onset (within 5 minutes) in reversible airways obstruction.

It is particularly suitable for the relief and prevention of asthma symptoms. It should be used to relieve symptoms when they occur, and to prevent them in those circumstances recognised by the patient to precipitate an asthma attack (e.g. before exercise or unavoidable allergen exposure).

Ventolin Evohaler is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.

Directions

Ventolin Evohaler is for oral inhalation use only. Ventolin Evohaler may be used with a Volumatic™ spacer device by patients who find it difficult to synchronise aerosol actuation with inspiration of breath.

Adults (including the elderly): For the relief of acute asthma symptoms including bronchospasm, one inhalation (100 micrograms) may be administered as a single minimum starting dose. This may be increased to two inhalations if necessary. To prevent allergen- or exercise-induced symptoms, two inhalations should be taken 10-15 minutes before challenge.

For chronic therapy, two inhalations up to four times a day.

Children: For the relief of acute asthma symptoms including bronchospasm, or before allergen exposure or exercise, one inhalation, or two if necessary.

For chronic therapy, two inhalations up to four times a day.

The BabyhalerTM spacer device may be used to facilitate administration to children under 5 years of age.

On-demand use of Ventolin Evohaler should not exceed 8 inhalations in any 24 hours. Reliance on such frequent supplementary use, or a sudden increase in dose, indicates poorly controlled or deteriorating asthma.

Warnings

Patients inhaler technique should be checked to make sure that aerosol actuation is synchronised with inspiration of breath for optimum delivery of drug to the lungs. Patients should be warned that they may experience a different taste upon inhalation compared to their previous inhaler.

Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment, including lung-function testing, as patients are at risk of severe attacks and even death. Physicians should consider using the maximum recommended dose of inhaled corticosteroid and/or oral corticosteroid therapy in these patients.

The dosage or frequency of administration should only be increased on medical advice. If a previously effective dose of inhaled salbutamol fails to give relief lasting at least three hours, the patient should be advised to seek medical advice.

Increasing use of bronchodilators, in particular short-acting inhaled β2-agonists, to relieve symptoms, indicates deterioration of asthma control. The patient should be instructed to seek medical advice if short-acting relief bronchodilator treatment becomes less effective, or more inhalations than usual are required. In this situation the patient should be assessed and consideration given to the need for increased anti-inflammatory therapy (e.g. higher doses of inhaled corticosteroid or a course of oral corticosteroid).

Severe exacerbations of asthma must be treated in the normal way.

Cardiovascular effects may be seen with sympathomimetic drugs, including salbutamol. There is some evidence from post-marketing data and published literature of rare occurrences of myocardial ischaemia associated with salbutamol. Patients with underlying severe heart disease (e.g. ischaemic heart disease, arrhythmia or severe heart failure) who are receiving salbutamol should be warned to seek medical advice if they experience chest pain or other symptoms of worsening heart disease. Attention should be paid to assessment of symptoms such as dyspnoea and chest pain, as they may be of either respiratory or cardiac origin.

Salbutamol should be administered cautiously to patients with thyrotoxicosis.

Potentially serious hypokalaemia may result from β2-agonist therapy, mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by hypoxia and by concomitant treatment with xanthine derivatives, steroids and diuretics. Serum potassium levels should be monitored in such situations.

Pack Size

1 pack

More Info ..

To view this product's Patient Information Leaflet, click here.